Mouse Model Generation
Recombineering (Red/ET recombination) has become the method of choice to engineer large replicons, such as targeting constructs (large high-copy plasmids, low-copy plasmids) or bacterial artificial chromosomes (BACs). Since recombineering can be performed at any position in the DNA the technology has opened up an unlimited number of possibilities for even complex genetic modifications.
With over 17 years experiences and the know-how from over 800 DNA engineering projects, Gen-H GmbH is the partner of choice for DNA modifications and animal model constructions with a quality “made in Germany”.
Gen-H’s scientists have been involved in collaborative research projects and functional genomics programes funded by the European Commission such as the “AgedBrainSYSBIO” which is a project with a high impact of human public health. As part of this project we successfully knocked in a 33 kb human fragment into the mouse ApoE locus.
Gen-H can assist you with its broad expertise in generating optimized (complex) mouse models.
Our services include:
- Personal and customer-oriented project discussion by our scientists
- Customized construct design
- Direct contact partner over the period of the project
- Screening strategies for genotyping
What we offer:
- Knock-out targeting constructs
- Conditional knock-out targeting constructs
- Knock-in targeting constructs (e.g. reporter genes, CRE-ERT2, point mutations, tags)
- Conditional knock-in targeting constructs (induction of point mutation in a temporal- and tissue specific manner by Cre recombination)
- Humanized targeting constructs
- Removal of “passenger genes” from a BAC clone (“BAC shaving”)
- BAC fusions (“BAC stitchings”)
- Humanized BAC transgenes
- Insertions or deletions
- Individually and specifically engineered lentiviral constructs used for viral vector-based gene therapy
Common schizophrenia risk variants are enriched in open chromatin regions of human glutamatergic Neurons; Mads E. Hauberg, Jordi Creus-Muncunill, Jaroslav Bendl, Alexey Kozlenkov, Biao Zeng, Chuhyon Corwin, Sarah Chowdhury, Harald Kranz, Yasmin L. Hurd, Michael Wegner, Anders D. Børglum, Stella Dracheva, Michelle E. Ehrlich, John F. Fullard and Panos Roussos; Nature Communications; 2020; 11: 5581
Humanization of a large genome fragment using CRISPR/Cas9 and Recombineering; Martina Reiss and Harald Kranz; Biospektrum 07/2017
- BIN1 genetic risk factor for Alzheimer is sufficient to induce early structural tract alterations in entorhinal cortex-dentate gyrus pathway and related hippocampal multi-scale impairments; R Daudin, D Marechal, Q Wang, Y Abe, N Bourg, M Sartori, Y Loe-Mie, J Lipecka, C Guerrera, A McKenzie, B Potier, P Dutar, J Viard, A.M Lepagnol-Bestel, A Winkeler, V Hindié, MC Birling, L Lindner, C Chevalier, G Pavlovic, M Reis, H Kranz, G Dupuis, S Lévêque-Fort, J Diaz, E Davenas, D Dembele, J Laporte, C Thibault-Carpentier, B Malissen, J.C Rain, L Ciobanu, D Le Bihan, B Zhang, Y Herault and M Simonneau; bioRxiv; 2018: 437228
- Lentiviral-based approach for the validation of cancer therapeutic targets in vivo; Chiara Ambrogio, Patrick Stern, Claudio Scuoppo, Harald Kranz, Mariano Barbacid and David Santamaría; BioTechniques, 2014; 57: 179
- Modeling human disease in rodents by CRISPR/Cas9 genome Editing; Marie‑Christine Birling, Yann Herault and Guillaume Pavlovic, Mamm Genome; 2017; 28: 291